Immunovia AB (IMMNOV):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Immunovia AB (IMMNOV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8274)・商品コード:DATA904C8274
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:35
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Immunovia AB (Immunovia) is a molecular diagnostics company that offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis, which can be used in the early diagnosis of cancer, predicting disease progression, and monitoring the therapeutic responsiveness of cancers. Immunovia’s IMMray can also be used for biomarker discovery through its discovery tool for proteome scanning. The company also provides IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. Its therapeutic areas include cancer and autoimmune diseases such as systemic lupus erythematosus. The company collaborates with various cancer centers for conducting clinical evidence studies. Immunovia is headquartered in Lund, Sweden.

Immunovia AB (IMMNOV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immunovia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Immunovia AB, Medical Devices Deals, 2012 to YTD 2018 9
Immunovia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Immunovia AB, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Immunovia Enters into Agreement with University of Pittsburgh 11
Immunovia Enters into Research Collaboration Agreement with Linkoping University 12
Immunovia to Enter into Agreement with National Cancer Institute 13
Immunovia Enters into Agreement with University of Liverpool 14
Immunovia Partners with OHSU Knight Cancer Institute 15
Equity Offering 16
Immunovia Raises USD37.3 Million in Private Placement of Shares 16
Immunovia Raises USD3.4 Million in Rights Offering of Shares 18
Immunovia Prices Private Placement of Shares for USD22.3 Million 20
Immunovia Plans to Raise Funds in Public Offering of Shares 21
Immunovia Raises USD7 Million in IPO 22
Immunovia AB – Key Competitors 23
Immunovia AB – Key Employees 24
Immunovia AB – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 24, 2018: Immunovia interim report, january-june 2018 26
Apr 27, 2018: Immunovia Interim report, January-March 2018 27
Feb 15, 2018: Immunovia Full Year report, January-December 2017 28
Nov 10, 2017: Immunovia Interim report, January-September 2017 29
Aug 23, 2017: Immunovia Interim report January-June 2017 30
Apr 20, 2017: Immunovia Interim report, January-March 2017 31
Feb 15, 2017: Immunovia Financial Statement 2016 32
Corporate Communications 33
Jul 17, 2017: Leading pancreatic cancer expert on early symptoms Professor Stephen Pereira at University College London joins Immunovia’s Scientific Advisory Board 33
Other Significant Developments 34
Jun 28, 2017: Immunovia Establishes US Headquarters, Including CLIA Reference Laboratory, in Boston 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Immunovia AB, Pharmaceuticals & Healthcare, Key Facts 2
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immunovia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immunovia AB, Deals By Therapy Area, 2012 to YTD 2018 8
Immunovia AB, Medical Devices Deals, 2012 to YTD 2018 9
Immunovia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Immunovia Enters into Agreement with University of Pittsburgh 11
Immunovia Enters into Research Collaboration Agreement with Linkoping University 12
Immunovia to Enter into Agreement with National Cancer Institute 13
Immunovia Enters into Agreement with University of Liverpool 14
Immunovia Partners with OHSU Knight Cancer Institute 15
Immunovia Raises USD37.3 Million in Private Placement of Shares 16
Immunovia Raises USD3.4 Million in Rights Offering of Shares 18
Immunovia Prices Private Placement of Shares for USD22.3 Million 20
Immunovia Plans to Raise Funds in Public Offering of Shares 21
Immunovia Raises USD7 Million in IPO 22
Immunovia AB, Key Competitors 23
Immunovia AB, Key Employees 24
Immunovia AB, Subsidiaries 25

List of Figures
Immunovia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immunovia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immunovia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Immunovia AB, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[Immunovia AB (IMMNOV):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8274)販売に関する免責事項を必ずご確認ください。
★調査レポート[Immunovia AB (IMMNOV):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆